ductus arteriosus PDA KATP channel novel drug targets a b s t r a c t Forty years ago, non-steroidal anti-inflammatory drugs were first reported to decrease systemic prostaglandin levels and promote ductus arteriosus (DA) closure. And yet, prolonged patency of the DA (PDA) remains a significant clinical problem, complicated by imperfect therapies and wide variations in treatment strategy. There are few pharmacologybased tools available for treating PDA (indomethacin, ibuprofen, and acetaminophen), or for maintaining DA patency (PGE 1 ) as is needed to facilitate corrective surgery for ductusdependent congenital heart defects. Unfortunately, all of these treatments are inefficient and are associated with concerning adverse effects. This review highlights novel potential DA drug targets that may expand our therapeutic repertoire beyond the prostaglandin pathway.
Introduction
The ductus arteriosus (DA) is a muscular artery that connects the fetal aorta and pulmonary artery, providing an integral shunt of the fetal circulation, essential for maintaining fetal wellbeing. In utero, the DA diverts approximately 90% of the right ventricular output away from the high-resistance pulmonary circulation and into the systemic umbilical-placental circulation where gas exchange can occur with maternal blood. 1 Postnatally, the DA normally closes within 72 hours after birth to facilitate perfusion of the newly-inflated lungs. Failure to close results in a persistent left-to-right shunt termed patent ductus arteriosus (PDA). PDA affects up to 80% of premature infants 2 and accounts for 5-10% of all congenital heart defects in term infants. 3 Hemodynamically significant PDA is associated with significant morbidities including neurodevelopmental impairment, intraventricular hemorrhage, pulmonary hemorrhage, respiratory distress syndrome, bronchopulmonary dysplasia, necrotizing enterocolitis (NEC), spontaneous intestinal perforation, and congestive heart failure. 4 On the other hand, in ductusdependent heart lesions, which account for 20-25% of all congenital heart defects, it is necessary that patency of the neonatal DA be maintained in order to preserve life-saving pulmonary or systemic circulation prior to corrective surgery. 5 The fetal DA has intrinsic tone and requires dilating factors to maintain its patency in utero. Nitric oxide (NO) and prostaglandin E 2 (PGE 2 ) induce vessel relaxation by activating cGMP/PKG and cAMP/PKA signaling, respectively. While NO and PGE 2 are typically considered primary mediators of DA dilation, other factors, including potassium (K þ ) channels, adenosine, and atrial naturetic peptide, also play a role. [6] [7] [8] [9] At birth, the DA constricts in response to the acute increase in oxygen (O 2 ) 33 In addition, while PDA therapies can be administered orally or intravenously, PGE 1 -mediated DA dilation requires continuous intravenous infusion, another significant limitation. Despite the inefficient nature of these current tools, relatively little effort has been expended over the last four decades to identify novel targets for pharmacology-based DA manipulation.
Towards specific DA-targeted therapies
Lack of progress towards novel DA drug development is not entirely unexpected given the low probability of success for drug development programs in general. A recent study, 34 the largest of its kind, reports that from 2005-2015 only 8.5 % of all industry-sponsored drug development programs ended in FDA approval. Moreover, the rate at which new drugs are validated and brought to market is staggeringly slow, with the average drug spending 8.14 years in clinical trials. 34 However, drugs with the highest likelihood of success target proteins with these key characteristics: druggability, enrichment in the tissue of interest, and demonstrated relevance to disease 35, 36 ( Fig. 1 ). Targets with some precedent for binding a drug-like molecule are considered part of the "druggable genome". 37 Most modern drugs act on receptors, enzymes, and ion channels/transporters. However, as the pharmaceutical industry devises new ways to target moieties such as protein-protein interactions and nucleic acids, the druggable genome will expand to include non-traditional targets. Accordingly, there will be room for expansion of the potential targets for DA therapy, beyond the PGE-pathway. Traditional and non-traditional potential DA drug target candidates listed in Table 1 , include novel targets identified as enriched in the DA, using array and RNA-seq analyses to identify the DA's unique transcriptional identity (reviewed by Yarboro et al., this issue). [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] In the majority of these studies, the DA was compared to the ascending aorta, a natural choice given their close proximity and the shared neural crest origin of each vessel's smooth muscle cells. 49 While these analyses are helpful, looking at DA-specific targets should be expanded to include a comparison to renal, mesenteric, and cerebral vessels, given the potential that novel drugs could, as do all current DA drugs, have adverse effects on these vascular 
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beds. 50 While it is unlikely that any candidate will be exclusively expressed in the DA, those that are significantly enriched lend themselves to the possibility of targeting them with a relatively low "Goldilocks" dose of drug-one that would have just the right effect on the DA, but would be insufficient to act on other tissues given low expression of the target in those tissues. 26 Additionally, several transcriptome studies analyzed changes in gene expression in preterm vs term-gestation vessels. This is important to consider given that PDA most often occurs in the setting of prematurity and that immature DAs are less responsive to indomethacin and often lack the smooth muscle machinery to maintain DA closure even if initial constriction is achieved. 51 Therefore, targeting pathways involved in fetal DA maturation may be key to developing therapies with a higher success rate in preterm infants. For instance, fetal DAs are significantly less responsive to oxygen-induced constriction than term-gestation vessels. [52] [53] [54] Therefore, novel PDA therapies that can compensate for a diminished response to O 2 by promoting endothelin signaling or blocking K þ channels might be more effective at closing premature vessels.
Insights from animal studies
Animal models of PDA have been informative regarding disease pathways that could be therapeutically targeted.
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Interestingly, PDA is the most common cardiac anomaly in dogs. Studies show a sex-linked genetic predisposition, with certain breeds and female dogs being at higher risk. [55] [56] [57] A similar sex-linked predisposition has been reported in humans 58 although this is not supported by more recent analyses. 59 Similarly, Brown Norway rats have a high prevalence of PDA, making them a popular experimental tool for identifying gene alterations in the setting of disease. ). 61 These animals not only give molecular insight into disease-causing mechanisms, they also provide established in vivo platforms for preclinical validation of second-generation PDA drugs.
Insights from human studies
Results of animal studies are not always faithful predictors of patient outcomes, 62 highlighting the need for human genetic studies. 63 A representative set of the more than 100 singlegene mutation syndromes featuring PDA that have now been identified 55, 64, 65 is listed in Table 1 . Many of these syndromes also feature complicated congenital heart defects, making it difficult to parse out whether PDA is a primary lesion or the result of other structural and hemodynamic anomalies. Therefore, identifying gene variants associated with non-syndromic PDA may be more informative for sporadically occurring PDA, which makes up the vast majority (90%) of all PDA cases. 66 Single nucleotide polymorphisms (SNPs) associated with PDA 26 or response to indomethacin 67 have also been reported (Table 1) , although it has been difficult to confirm these findings in replication cohorts.
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Proof of concept
Interestingly, targets of current PDA therapeutics fulfill all three of the key characteristics of successful drug targets illustrated in Figure 1 . Indomethacin, ibuprofen, and acetaminophen all inhibit COX enzymes encoded by PTGS1 and PTGS2 genes. These enzymes catalyze PGE 2 synthesis, which subsequently regulates DA tone by binding to the DAenriched receptor, PTGER4. Mice lacking these enzymes or the receptor have a lethal PDA phenotype, 44, [70] [71] [72] [73] demonstrating relevance of these targets to this disease. Therefore, it may be reasonable to assume that novel DA drug targets with the best chance of having clinical success will conform to a similar pattern. As one example, K ATP channels possess all three key characteristics listed above. These channels are hetero-octameric complexes of pore-forming inward rectifier K þ channel subunits (Kir6.1 or Kir6.2) and regulatory sulfonylurea receptor subunits (SUR1, SUR2A, or SUR2B). Channel isoforms have distinct pharmacological and physiological characteristics and are expressed in a tissue-specific manner (Table 2) , making them potentially ideal targets for DAselective therapies. 74 A regulatory link between K ATP channels and DA tone is becoming increasingly apparent. Vascular K ATP channels, formed of the Kir6.1/SUR2B isoform combination, are developmentally regulated and significantly enriched in the DA compared to other vessels. [38] [39] [40] [41] [42] 45, 48 Animal studies have
shown that the DA constricts in response to glibenclamide, 12,75 a non-specific K ATP channel inhibitor commonly used to treat diabetes. Conversely, fetal or neonatal exposure to diazoxide, a K ATP channel activator, inhibited DA constriction in rats, 76 and was reported to cause DA reopening in hypoglycemic infants. 77 Most notably, 50% of patients with Cantu syndrome, caused by activating mutations in Kir6.1 or SUR2B, have a clinically significant PDA that is often resistant Table 2 -Isoform-specific expression of K ATP channel subunits.
to indomethacin therapy, thus requiring surgical ligation to achieve closure. 78 Capitalizing on the druggability and therapeutic potential of K ATP channels, several groups, including our own, are working to develop subunit-specific activators and inhibitors. 79, 80 Using a thallium flux-based high-throughput screen, we identified a very potent novel K ATP channel agonist (VU063), with preferential activity towards the pancreatic/neuronal channel isoform (Kir6.2/SUR1).
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We performed pressure myography assays on mouse DAs as previously described 41, 81 to test the specificity and vasoactive potential of this compound (Fig. 2) . As expected, the SUR2-preferring K ATP channel activator, pinacidil, dilated the DA in a dose-dependent manner, but VU063 had no effect on DA tone. Thus, while VU063 would, just like diazoxide, be conducive for treating hyperinsulinemia, unlike diazoxide it would not induce off-target vascular effects. Along these lines, it is likely that future studies will identify small molecule antagonists/agonists that preferentially target the vascular channel isoform (Kir6.1/SUR2B), which will allow for a more specific way to modulate DA tone.
Perspective and prospects
In the 45 years since the first reports of indomethacininduced DA closure, [16] [17] [18] 29, 82, 83 relatively little headway has been made in developing novel approaches for therapeutic modulation of DA tone. As a consequence, there has been little progress in establishing a standard of care over the subsequent decades, leading to significant variability in treatment strategies amongst neonatal care centers and even between providers in a single care center. 84, 85 As we learn more about the DA, it is becoming clear that PDA is a deceptively complex condition that will likely benefit more from personalized medicine rather than a one-pathway-fits all approach to therapeutics. In lieu of redundant retrospective case analyses, a greater emphasis should be placed on multidisciplinary efforts to identify DA-modulating pathways outside of the prostaglandin signaling cascade and to develop specific pharmacological modifiers of those targets.
Moving towards this goal, increased access to human tissue repositories 86 coupled with the ability to perform large-scale GWAS and other genome-wide studies will uncover new PDA-associated genes. Furthermore, these studies will provide important pharmacogenetic information that could be used at the bedside to prospectively determine the likelihood of an individual patient responding to indomethacin, thereby shielding non-responders from unnecessary exposure. 87 Moreover, emerging technologies including the generation of tissue-engineered ductus vessels 88 and the creation of immortalized human DA cell lines for use in high-throughput small molecule screens will provide novel tools to identify and validate second generation DA drugs, setting the stage for rapid advances towards novel DA therapeutic development.
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